

台灣神經內分泌腫瘤學會 2023 春季會

時間：2023/04/08 (Saturday) 13:30~17:30

地點：台北喜來登大飯店 B1 玉瀾+蒼萃廳 (地址：台北市忠孝東路一段 12 號)

主辦：台灣神經內分泌腫瘤學會

報名費：會員免費；非會員 1,000 元 (現場繳納)

報到時間：12:30~

Time	Topic	Speaker	Moderator
13:00 ~ 13:25	理監事會議		
13:25 ~ 13:30	Opening	<u>陳立宗</u> 理事長	
13:30 ~ 14:20	Education program: Von Hippel–Lindau disease (VHL)	<u>陳明晃</u> 醫師 台北榮民總醫院 腫瘤醫學部	<u>黃燦龍</u> 名譽理事長
14:20 ~ 15:00	Real-world use of SSA & finding optimal options for long-term injections with less pain for GEP-NETs patients. ~Sponsored by Ipsen	<u>廖思嘉</u> 醫師 台中榮總 胃腸肝膽科	<u>王秀伯</u> 教授 台大胃腸肝膽科
15:00 ~ 15:20	Coffee Break		
Neuroendocrine carcinoma: The overview and treatment strategies of neuroendocrine carcinoma (NEC)			
15:20 ~ 15:50	Pulmonary neuroendocrine carcinoma	<u>李日翔</u> 醫師 台大新竹分院 腫瘤醫學部	<u>施翔蓉</u> 醫師 台大代謝內分泌科
15:50 ~ 16:20	Gastrointestinal and pancreatic neuroendocrine carcinoma	<u>邱泰然</u> 醫師 高雄長庚血液腫瘤科	<u>陳仁熙</u> 教授 林口長庚血液腫瘤科
16:20 ~ 16:50	Gynecological and prostate neuroendocrine carcinoma	<u>吳佳哲</u> 醫師 高雄長庚血液腫瘤科	<u>吳宜珍</u> 主任 高醫胃腸內科
16:50 ~ 17:20	Panel discussion		

學會教育積分：(申請中)

台灣外科醫學會	台灣內科醫學會
台灣消化系外科醫學會	台灣消化系醫學會
台灣內視鏡外科醫學會	台灣消化系內視鏡醫學會
中華民國內分泌學會	中華民國癌症醫學會

Curriculum Vitae

Name :

Ming-Huang Chen MD., Ph.D.

Business Address :

No. 201, Section 2, Shih-Pai Rd, Taipei, 11217, Taiwan

Professional Experience :

2023-present, Director ,Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital

2021-present, Secretary General, Taiwan Oncology Society

2020-2023, Director of Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital

2017-2019, Attending physician, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2021, Professor, National Yang Ming Chiao Tung University, Taiwan

2017, Visitor, National Cancer Center, Tokyo, Japan

2011, Visitor, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (USA)

Education and medical Training :

<Education>

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

<Medical training>

2005-2008 Fellowship in Division of Hematology & Oncology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2002-2005 Residency, Department of Internal Medicine

2001-2002 Internship, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

Board Certification :

Board of Oncology

Board of Hematology

Board of the Internal Medicine

Board of Hospice care

Board of Bone Marrow Transplantation

Memberships :

Taiwan Oncology Society

The Society of Internal Medicine

American Society of Clinical Oncology

European Neuroendocrine Tumor Society

Study Experiences**IIT trial**

1. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, **Chen MH**. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract

Cancer: A Phase II T1219 Study. Clin Cancer Res. 2022 Oct 3;28(19):4248-4257.

2. **Chen MH**, et al. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. Medicine (Baltimore). 2016 Jan;95(3):e2565.

3. **Chen MH**, et al. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects with Poorly Differentiated Neuroendocrine Carcinomas, Oncologist. 2020 May;25(5):e782-e788

Publications (only first author or corresponding author):

Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DSS, Wu CE, Lai JI, Chang PMH, **Chen MH**, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. PRKDC: New Biomarker and Drug Target for Checkpoint Blockade Immunotherapy. J Immunother Cancer. 2020 Mar;8(1):e000485

Pan YR, Wu CE, Wang YC, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JCH, **Chen MH**[#] and Chun-Nan Yeh[#]. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response.. Accepted by Clinical & Translational Immunology

Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST). Might Be a More Promising Immune Biomarker in Colorectal Cancer... Oncologist. 2019 Dec;24(12):1534-1542.

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. Clin Cancer Res. 2016 Aug 15;22(16):4225-35.

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, **Chen MH**^{*}, Yeh CN. MET RON dual inhibitor, BMS 777607, suppresses cholangiocarcinoma cell growth, and MET RON upregulation indicates worse prognosis for intra hepatic cholangiocarcinoma patients. Oncol Rep. 2018 Sep;40(3):1411-1421.

Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, **Chen MH**, Hung YP, Li CP, Chao Y, Chen MH. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. Int J Biol Sci. 2016 Nov 25;12(12):1523-1532.

Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget. 2015 Sep 15;6(27):23594-608.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang

CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. *Oncotarget*. 2014;5:2372-89.

Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. *Ann Surg Oncol*. 2013;20:616-24.

Chen MH, Lin KJ, Yang WLR, Kao YW, Chen TW, Chao SC, Chang PMH, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CYF. Gene Expression-Based Chemical Genomics Identifies Heat Shock Protein 90 Inhibitors as Potential Therapeutic Drugs in Cholangiocarcinoma. *Cancer*. 2013;119:293-303.

Chen MH, Yeh YC, ShyrYM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PMH, Liu CY, Chen MH, Hsiao M, Huang CYF. Expression of Gremlin 1 Correlates with Increased Angiogenesis and Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. *Journal of Gastroenterology*. 2013;48:101-8.

Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. *PLoS One*. 2011;6:e27186.

CURRICULUM VITAE

NAME: Szu-Chia Liao

OFFICE: Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan

TEL: +886-4-23592525 ext 3306

FAX: +886-4-23741331

E-mail: b8401084@gmail.com

DATE OF BIRTH: June 29, 1977

MEDICAL EDUCATION:

M.D., Taipei Medical University, Taipei, Taiwan 1995-2002

M.D., Department of Public Health, China Medical University, Taichung, Taiwan 2010-2014

QUALIFICATIONS:

National Medical Board, Taiwan

2002

Board of Taiwan Society of Internal Medicine

2005

Board of the Gastroenterological Society of Taiwan 2007

PRESENT HOSPITAL POSITION:

Fellowship, in Division of Gastroenterology, Taichung Veterans General Hospital
2005 – 2007

Fellowship, in Center of Geriatrics and Gerontology, Taipei Veterans General
Hospital 2007 – 2008

Lecturer in clinical medicine, in National Defense Medical Center 2006 – Now

Physician, in Division of Gastroenterology, Taichung Veterans General Hospital

2008 – Now

SUMMARY OF POSTGRADUATE EDUCATION:

Resident in Internal Medicine, Taichung Veterans General Hospital 2002-2005

Chief Resident in Gastroenterological Medicine, Taichung Veterans General
Hospital 2005-2007

Research Fellowship in Division of Geriatric Medicine, Center for Geriatrics and
Gerontology, Taipei Veterans General Hospital.

2007-2008

Master of Science in Department of Public Health, China Medical University

2010–2013

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

Taiwan Society of Internal Medicine 2002 – Now

Taiwan Gastroenterological Society 2005 – Now

The Society of Ultrasound in Medicine, R.O.C. 2005 – Now

Taiwan Association of Gerontology and Geriatrics 2007 – Now

Member of American Society of Gastrointestinal Endoscopy 2018
- Now

Member of World Endoscopy Organization

2019 - Now

PUBLICATIONS OF LIAO SZU-CHIA

A: REFERRED PAPERS

1. **Szu-Chia Liao, M.D.**, Chung-Wang Ko, M.D., Hong-Zen Yeh, M.D., Chi-Sen Chang, M.D., Sek-Kwong Poon, M.D., Sheng-Shun Yang, M.D., Han-Chung Lien, M.D., Gran-Hum Chen, M.D. Successful treatment of persistent bacteremia after endoscopic injection of N-Butyl-2-cyanoacrylate for gastric varices bleeding. *Endoscopy* 2007; 39: E176-E177
2. **Liao SC**, Yang SS, Ko CW, Lien HC, Tung CF, Peng YC, Yeh HZ, Chang CS. A miniature ultrasound probe is useful in reducing rebleeding after endoscopic cyanoacrylate injection for hemorrhagic gastric varices. *Scand J Gastroenterol.* 2013 Nov;48(11):1347-53.
3. Lin MS, **Liao SC**, Peng YC, Yang SS, Yeh HZ, Chang CS. Application of endoscopic US-guided tissue adhesive injection as a rescue therapy for post-tissue adhesive variceal obturation-related gastric wall bleeding. *Gastrointest Endosc.* 2014 Mar;79(3):514-5
4. **Liao SC**, Ko CW, Yeh HZ, Chang CS. Severe diarrhea caused by cytomegalovirus in an elderly man. *Advances in Digestive Medicine* (2015)2, 141-144
5. Sheng-Shun Yang, **Szu-Chia Liao**, Chun-Wang Ko, Chun-Fang Tung, Yen-Chun Peng, Han-Chung Lien, Hong-Zen Yeh, Chi-San Chang, Jong Wang. The clinical efficacy and safety of EUS-FNA for diagnosis of mediastinal and abdominal solid tumors – A single center experience. *Advances in Digestive Medicine* (2015)2, 61-66.
6. Yu-Chiao Chiu, Chia-Chang Chen, Chung-Wang Ko, **Szu-Chia Liao**, Hong-Zen Yeh, Chung-Hsin Chang. Real-world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan. *Advances in Digestive Medicine* (2020)19, 1-7
7. Szu-Chia Liao, Hong-Zen Yeh, Chi-Sen Chang, Wei-Chih Chen, Chih-Hsin Muo and Fung-Chang Sung. Colorectal Cancer Risk in Women with Gynecologic Cancers—A Population Retrospective Cohort Study. *J. Clin. Med.* (2021) 10, 3127

B: CONFERENCE PAPERS

1. **Szu-Chia Liao, M.D.**, Hong-Zen Yeh, M.D., Chi-Sen Chang, M.D., Gran-Hum Chen, M.D. The evaluation of the efficacy and safety of endoscopic ultrasound guided trucut biopsy in the diagnosis of gastrointestinal tumorous lesions. 2006 Annual meeting of the gastroenterological society of Taiwan and the digestive endoscopy society of Taiwan
2. **Szu-Chia Liao, M.D.**, Ming-Shien Lin, Hong-Zen Yeh Diagnosis and prognosis of solid pseudopapillary tumor of the pancreas: experience of one single institution from middle part of Taiwan. 2017 Annual meeting of the gastroenterological society of Taiwan and the digestive endoscopy society of Taiwan
3. **Szu-Chia Liao, M.D.**, Cheng-Chung Wu, Hong-Zen Yeh Diagnosis and prognosis by endoscopic ultrasound in patients with neuroendocrine tumor of the pancreas: a case series of 20-year-experience from a single institution at central Taiwan. 2017 Annual meeting of the gastroenterological society of Taiwan and the digestive endoscopy society

- of Taiwan
4. **Szu-Chia Liao, M.D.**, Hong-Zen Yeh, Chi-Sen Chang, Wei-Chih Chen, Muo CH, Fung-Chang Sung, PhD, MPH Subsequent Colorectal Risk among Women with Gynecologic Cancer-A Population Cohort Study. 2018 Annual meeting of the gastroenterological society of Taiwan and the digestive endoscopy society of Taiwan
 5. **Szu-Chia Liao, M.D.**, Cheng-Chung Wu, Hong-Zen Yeh Diagnosis and prognosis by endoscopic ultrasound in patients with neuroendocrine tumor of the pancreas: a case series of 20-year-experience from a single institution at central Taiwan. 2018 AOPA & KPBA & KPSC
 6. Fang-Wei Chiu, M.D., **Szu-Chia Liao, M.D.**, Lin Wan-Tzu, M.D., Chung-Shin Chang, M.D., Chung-Wang Ko, M.D., Hong-Zen Yeh M.D. The clinical outcome of obscure overt GI bleeding after initial enteroscopy. 2019 Annual meeting of the gastroenterological society of Taiwan and the digestive endoscopy society of Taiwan
 7. **Szu-Chia Liao, M.D.**, Yin-Chen Lin, M.D., Liao Yi-Jun, M.D., Hong-Zen Yeh M.D. Endoscopic ultrasound approach of pancreatic mass in chronic pancreatitis patients in the era without elastography and contrast-enhanced endoscopic ultrasound: a 13-year-experience of one single institution. 2019 DDW

CURRICULUM VITAE

Personal Data

Name: Jih-Hsiang Lee (李日翔), M.D.

Date of birth: May-19-1977

Place of birth: Tainan, Taiwan

Office

Department of Oncology, National Taiwan University Hospital, Hsin-Chu Branch
NO.25,Lane 442,Sec.1,Jingguo Rd.,Hsinchu City 300,Taiwan

Tel: 886-3-5326151 ext 34502

Fax: 886-2-23711174

e-mail: leejihhsiang@ntu.edu.tw

Current Positions and previous experiences

- Chief, Department of Oncology, National Taiwan University Hospital (NTUH), Hsin-Chu branch Jan, 2021-present
- Chief, Center of Oncology Medicine, National Taiwan University Hospital (NTUH), Hsin-Chu Branch Aug, 2017-Dec, 2020
- Attending physician, Department of Oncology, National Taiwan University Hospital (NTUH), Taiwan Jul, 2017-present
- Attending physician, Department of Medical Research, National Taiwan University Hospital (NTUH), Taiwan Feb, 2015-Jul, 2017
- Attending physician, National center of excellence for clinical trial and research, National Taiwan University Hospital, Taiwan. Oct, 2008-Feb, 2015
- Member of the Research Ethic Committee, NTUH. Jul., 2012-present

Medical Education

M.D. School of Medicine, Medical College, National Taiwan University, Taiwan
Sep., 1993-Jun., 2000

Postgraduate Training

- Resident, Department of Internal Medicine, NTUH, Taiwan Jul., 2002-Jun., 2005
- Fellow, Department of Oncology, NTUH, Taiwan Jul., 2005-Jun., 2008
- Fellow, Section of hematology, department of internal medicine, NTUH, Taiwan Jul., 2007-Jun., 2008
- Visiting fellow, Dr. Giuseppe Giaccone's laboratory, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, USA May, 2009-Jan., 2012

Medical License

- Board of Medicine, Taiwan (2000-)
- Board of Internal Medicine, Taiwan (2005-)
- Board of Medical Oncology, Taiwan (2007-)
- Board of Cancer Palliative Medicine, Taiwan (2015-)

Membership:

- Member, Taiwan Society of Internal Medicine, Taiwan
- Member, Chinese Society of Cancer, Taiwan
- Member, Taiwan Society of Cancer Palliative Medicine, Taiwan
- Member, International Association for Study of Lung Cancer

- Member, Taiwan Association for Study of Lung Cancer

Honorship

- Young Investigator Award of the International Association for Study of Lung Cancer (IASLC), 2012-2014

Publication:

1. **Lee JH**, Cheng AL, Lin CW, Kuo SH: Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application. *The British journal of dermatology* 160:887-9, 2009
2. **Lee JH**, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH: Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. *Journal of the Formosan Medical Association = Taiwan yi zhi* 109:338-44, 2010
3. Voortman J*, **Lee JH***, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al: Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. *Proceedings of the National Academy of Sciences of the United States of America* 107:13040-5, 2010 (co-first authors)
4. **Lee JH**, Voortman J, Dingemans AM, Voeller DM, Pham T, Wang Y, et al: MicroRNA expression and clinical outcome of small cell lung cancer. *PloS one* 6:e21300, 2011
5. Wu SG, Yang CH, Yu CJ, **Lee JH**, Hsu YC, Chang YL, et al: Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. *Lung cancer* 72:333-9, 2011
6. **Lee JH**, Giovannetti E, Hwang JH, Petrini I, Wang Q, Voortman J, et al: Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 18:524-33, 2012
7. Weng MT, **Lee JH**, Wei SC, Li Q, Shahamatdar S, Hsu D, et al: Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. *Proceedings of the National Academy of Sciences of the United States of America* 109:E3659-67, 2012
8. Chen JQ*, **Lee JH***, Herrmann MA, Park KS, Heldman MR, Goldsmith PK, et al: Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. *Molecular cancer therapeutics* 12:2601-13, 2013 (co-first authors)
9. Huang MH, **Lee JH**, Chang YJ, Tsai HH, Lin YL, Lin AM, et al: MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. *Molecular oncology* 7:112-20, 2013
10. **Lee JH**, Park KS, Alberobello AT, Kallakury B, Weng MT, Wang Y, et al: The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo. *Clinical cancer research : an official journal of the American Association for Cancer Research* 19:6777-86, 2013
11. Giovannetti E, Wang Q, Avan A, Funel N, Lagerweij T, **Lee JH**, et al: Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. *Journal of the National Cancer Institute* 106:djt346, 2014
12. **Lee JH***, Lin YL*, Hsu WH, Chen HY, Chang YC, Yu CJ, et al: Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 9:1385-92, 2014 (co-first authors)
13. Thomas A*, **Lee JH***, Abdullaev Z, Park KS, Pineda M, Saidkhodjaeva L, et al: Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 9:567-71, 2014 (co-first authors)
14. Liao BC, **Lee JH**, Lin CC, Chen YF, Chang CH, Ho CC, et al: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer

Patients with Leptomeningeal Carcinomatosis. *J Thorac Oncol* 10:1754-61, 2015

15. Lin CH, Shen CY, **Lee JH**, Huang CS, Yang CH, Kuo WH, et al: High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. *PloS one* 10:e0124908, 2015

16. Weng MT, Tung TH, **Lee JH**, Wei SC, Lin HL, Huang YJ, et al: Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. *Scientific reports* 5:9357, 2015

17. Hsiue EH, **Lee JH**, Lin CC, Yang JC. Safety of gefitinib in non-small cell lung cancer treatment. *Expert Opin Drug Saf* 2016;15:993-1000

18. Minami H, Ando Y, Ma BB, **Lee JH**, Momota H, Fujiwara Y, et al. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. *Cancer Science* 2016;107(10):1477-1483.

19. Hsiue EH, **Lee JH**, Lin CC, Yang JC. Profile of the theascreen® EGFR RQO PCR Kit as a companion diagnostic for gefitinib in non-small cell lung cancer. *Expert Rev Mol Diagn.* 2016;16(12):1251-1257

20. Liao BC, Lin CC, **Lee JH**, Yang JC. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. *J Biomed Sci* 2016;23:86

21. Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, **Lee JH**, et al. Genetic Modifiers of Progression-free Survival in Never-smoking Lung Adenocarcinoma Patients Treated with First-line TKIs. *Am J Respir Crit Care Med* 2017;195(5):663-673

22. Liao BC, Bai YY, **Lee JH**, Lin CC, Lin SY, Lee YF, Ho CC et al. Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. *J Formos Med Assoc* 2017;17:30353-4.

23. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, **Lee JH** et al. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. *Oncotarget* 2017;8(25):41474-41486.

24. Wu TH, Hsiue EH, **Lee JH**, Lin CC, Yang JC. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. *Expert Rev Respir Med* 2017;1:51-55

25. Liao BC, Lin CC, **Lee JH**, Yang JC. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. *Lung Cancer* 2017;110:7-13

26. Wu TH, Hsiue EH, **Lee JH**, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. *Clin Lung Cancer* 2018;19:e361-72.

27. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, **Lee JH** et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. *Lancet Respir Med* 2018;6:107-116.

28. Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, **Lee JH** et al. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. *J Cancer* 2018;9:1813-20.

29. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, **Lee JH**, Lin ZZ, Shih JY, Yang JC, Yu CJ. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. *Int J Cancer* 2019;144(11):2887-2896

30. **Lee JH**, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid

tumors. *Invest New Drugs*. 2020;38(1):99-110

31. **Lee JH**, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. *Oncologist*. 2019;24(12):e1417-e1425

32. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, **Lee JH**, Lin CC, Shih JY, Yang JC, Yu CJ. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. *Eur J Cancer* 2020;124:110-122

33. de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, **Lee JH**, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkova N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. *Br J Cancer* 2020;129(9):1324-1332.

34. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, **Lee JH**, Lin CC, Shih JY, Yang JC, Yu CJ. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. *The Oncologist* 2020 Aug;25(8):702-711

35. Liao BC, Hsu WH, **Lee JH**, Yang CY, Tsai TH, Liao WY, Ho CC, Lin CC, Shih JY, Yu CJ, Soo RA, Yang JC. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in *EGFR* T790M-Positive NSCLC. *JTO Clin Res Rep*. 2020 Sep 19;2(1):100099

36. Jablonska PA, Fong CH, Kruser T, Weiss J, Liu ZA, Takami H, Narita Y, Ynoe de Moraes F, Dasgupta A, Ong CK, Yang JCH, **Lee JH**, Pavlakis N, Kongkham P, Butler M, Shultz DB. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. *Radiother Oncol*. 2022 Mar;168:89-94

37. Chang CF, Yang MH, **Lee JH**, Shih SR, Lin CH, Chen CP, Wu CE, Lu JY. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan. *Am J Cancer Res*. 2022 Nov 15;12(11):5342-5350.

38. Huang MH, **Lee JH**, Hung PS, Chih-Hsin Yang J. Potential Therapeutic Strategy for *EGFR*-Mutant Lung Cancer With Concomitant *EML4-ALK* Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors. *JTO Clin Res Rep*. 2022 Sep 9;3(11):100405.

39. Chang CL, Hsieh MS, Shih JY, Lee YH, Liao WY, Hsu CL, Yang CY, Chen KY, **Lee JH**, Ho CC, Tsai TH, Yang JC, Yu CJ. Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. *Ther Adv Med Oncol*. 2022 Oct 27;14:17588359221133889

CURRICULUM VITAE

Tai-Jan Chiu (邱泰然)

PERSONAL INFORMATION

Birthday: December, 29, 1972

Citizen: Kaohsiung, Taiwan

CONTACT INFORMATION

Tai-Jan Chiu

Department of Oncology, Chang Gung Memorial Hospital, Kaohsiung
Medical Center

123, Ta-Pei Rd, Niao-Sung Hsiang, Kaohsiung County, 833 Taiwan

E-mail: chiutaijan@gmail.com

Phone: +886-7-7317123 ext 8303

Mobile: +886975056060, +886918653389

Language: Chinese, Taiwanese, English

Education:

1. Jul-1992~Jun-1999; Kaohsiung Medical University; Kaohsiung, Taiwan
2. An undergraduate Ph.D. of Graduate Institute of Clinical Medical Sciences ,
Chang Gung University since Sep-2013

Employment Record :

1. From August 1, 2001 to July 31, 2002, as a first-year resident in
Department of Internal Medicine of Kaohsiung Medical University
Chung-Ho Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
2. From September 1, 2002 to August 31, 2004, as a second to third year
resident in Department of Internal Medicine of Chang Gung Memorial
Hospital, Kaohsiung, Taiwan, R.O.C.
3. From September 1, 2004 to August 31, 2006 as a first to second year
fellow in Division of Hemato-Oncology, Chang Gung Memorial Hospital,
Kaohsiung, Taiwan.
4. From September 2006 till now, as an attending physician of Division
of Hemato - Oncology, Departments of Internal Medicine, Chang Gung
Memorial Hospital, Kaohsiung,
5. From February 2011 to January 2013, as a visiting scientist of
Department of Molecular and Cellular Oncology of MD Anderson Cancer
center

LICENSURES : Physician License: Taiwan License NO: 30745

Internal Medicine: Bordered on 13. Jan. 2004,

Licence number : 006781

Medical Oncology: Bordered on 06.Nov.

Licence number: 96014

PUBLICATIONS

1. **Tai-Jan Chiu**, Yi-Ju Chen, Cheng-Hua Huang. Massive anterior chest wall metastasis of ovarian cancer and prolonged survival after treatment: a case report. [J Reprod Med](#). 2008 May;53(5):373-7.
2. **Tai-Jan Chiu**; Jun-Wen Wang; Yi-Ju Chen; Yeh Tang; Cheng-Hua Huang. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan. [Chang Gung Med J](#). 2009 Jan-Feb;32(1):72-80.
3. Chien-Ting Liu, **Tai-Jan Chiu**, Tai-Lin Huang, Chih-Yen Chien, Fu-Min Fang. Impact of Comorbidity on Survival for Locally Advanced Head and Neck Cancer Patients Treated by Radiotherapy or Radiotherapy plus Chemotherapy. [Chang Gung Med J](#). 2010 May-June;33(3):283-291.
4. Yu-Li Su, Chien-Ting Liu, **Tai-Jan Chiu**, Shan-Hsuan Li, Tai-Lin Huang, Yen-Yang Chen, Yen Tang, Kun-Ming Rau, Cheng-Hua Huang. Metastatic Mucinous Colorectal Cancer: An Important Subtype of Colorectal Cancer with Poor Response to Chemotherapy and Overall Survival. *J. Cancer Res. Pract.* 26(6), 221-230, 2010
5. **Chiu, Tai-Jan**, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. *J Transl Med*. 2011 Mar 23;9:31
6. Chen YJ, Rau KM, Chien CY, Fang FM, Huang TL, **Chiu, Tai-Jan**. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma. *Asian Pac J Cancer Prev*. 2011;12(3):649-55
7. Wu Chia-Che, **Tai-jan chiu**, Meng-Chih Lin, Jui-Ling Wang, Kun-Ming Rau, Chen YY, Huang CH*. Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : A *retrospective analysis*. 2011;27:157-164.
8. Rau KM, Huang CC, **Chiu TJ**, Chen YY, Lu CC, Liu CT, Pei SN, Wei YC. [Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers](#). *Exp Ther Med*. 2012 Aug;4(2):231-236.
9. **Chiu TJ**, Chen YJ, Rau KM, Chen CH, Chien CY, Li SH, Tsai HT, Eng HL. Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma. *Biomarkers*. 2013 Oct 28.
10. Hwang CF, Shiu LY, Su LJ, Yu-Fang Yin, Wang WS, Huang SC, **Chiu TJ**, Huang CC, Zhen YY, Tsai HT, Fang FM, Huang TL, Chen CH. Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis. *PLoS One*. 2013 Dec 27;8(12):e84218
11. Ming-Chun Ma, Yen-Yang Chen, Shau-Hsuan Li, Yu F. Cheng, Chih-Chi Wang, **Tai-Jan Chiu**, Sung-Nan Pei, Chien-Ting Liu, Tai-Lin Huang, Cheng-Hua Huang, Yu-Li Su, Yen-Hao Chen, Sheng-Nan Lu and Kun-Min Rau. Intraarterial Chemotherapy with Doxorubicin and Cisplatin is Effective for

Advanced Hepatocellular Cell Carcinoma. The Scientific World Journal Volume 2014 (2014), Article ID 160138, 8 page

12. Li SH, Lin WC, Huang TL, Chen CH, **Chiu TJ**, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. *Head Neck*. 2015 Apr 27
13. Chen CH, Chang AY, Li SH, Tsai HT, Shiu LY, Su LJ, Wang WL, **Chiu TJ**, Luo SD, Huang TL, Chien CY. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer. *Mol Cancer*. 2015 Apr 12;14:83
14. Sheng-Dean Luo, Yi-Ju Chen, Chien-Ting Liu, Kun-Ming Rau, Yi-Ching Chen, Hsin-Ting Tsai, Chang-Han Chen, **Tai-Jan Chiu**; Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma, *BioMed Research international* 2015; 2015: 508587
15. Yang MC, Wang HC, Hou YC, Tung HL, **Chiu TJ**, Shan YS. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. [Mol Cancer](#). 2015 Oct 12;14(1):179.
16. Su YY, Chien CY, Luo SD, Huang TL, Lin WC, Fang FM, **Chiu TJ**, Chen YH, Lai CC, Hsu CM, Li SH. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. *World J Surg Oncol*. 2016 Mar 22;14:86.
17. Fang FM, Chuang HC, Chou SY, Huang TL, Wang CJ, Lin YT, **Chiu TJ**, Lin WC, Li SH, Su YY, Chien CY. The Therapeutic Benefit of Radical Resection for T4b Oral Cavity Squamous Cell Carcinoma with Partial or Complete Response After Radical Chemo-Intensity-Modulated Radiotherapy (IMRT). *Ann Surg Oncol*. 2016 Dec;23(Suppl 5):866-873.
18. Chen CH, Tsai HT, Chuang HC, Shiu LY, Su LJ, **Chiu TJ**, Luo SD, Fang FM, Huang CC, Chien CY. Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A. *Sci Rep*. 2017 May 2;7(1):1358.
19. **Tai-Jan Chiu**, Sheng-Dean Luo, Chih-Yen Chien, Yan-Ye Su, Tai-Lin Huang, Wei-Che Lin, Fu-Min Fang, Chang-Han Chen, Shun-Yu Su, Shau-Hsuan Li. Treatment Outcome of Patients with Unresectable Stage IVB Head and Neck Squamous Cell Carcinoma Receiving Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil. *International Journal of Head and Neck Science* 1(2): 121-130, 2017
20. Rau KM, Su YL, Li SH, Hsieh MC, Wu SC, Chou FF, **Chiu TJ**, Chen YH, Liu CT. High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. *Mol Med Rep*. 2017 Nov;16(5):7185-7190. doi: 10.3892/mmr.2017.7555.
21. Ma MC, Chen YJ, **Chiu TJ**, Lan J, Liu CT, Chen YC, Tien HH, Chen YY. Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. *BMC Cancer*. 2018 Feb 27;18(1):227.
22. **Tai-Jan Chiu**. Combinatorial Methods of Immunotherapy Open New Opportunities in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Review article. *International Journal of Head and Neck Science* 2(1): 5-13, 2018
23. Ma MC, **Chiu TJ**, Lu HI, Huang WT, Lo CM, Tien WY, Lan YC, Chen YY, Chen CH, Li SH. SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma. *J Cardiothorac Surg*. 2018 Apr 10;13(1):25.

24. **Chiu TJ**, Lu HI, Chen CH, Huang WT, Wang YM, Lin WC, Li SH.
Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. *Biomed Res Int*. 2018 Apr
25. Lee PC, Fang YF, Yamaguchi H, Wang WJ, Chen TC, Hong X, Ke B, Xia W, Wei Y, Zha Z, Wang Y, Kuo HP, Wang CW, Tu CY, Chen CH, Huang WC, Chiang SF, Nie L, Hou J, Chen CT, Huo L, Yang WH, Deng R, Nakai K, Hsu YH, Chang SS, **Chiu TJ**, Tang J, Zhang R, Wang L, Fang B, Chen T, Wong KK, Hsu JL, Hung MC. Targeting PKC δ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. *Cancer Cell*. 2018 Dec 10;34(6):954-969.e4. doi: 10.1016/j.ccell.2018.11.007.
26. Wang HC, Lin YL, Hsu CC, Chao YJ, Hou YC, **Chiu TJ**, Huang PH, Tang MJ, Chen LT, Shan YS. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. *Theranostics*. 2019 Sep 23;9(24):7168-7183. doi: 10.7150/thno.36830. eCollection 2019.
27. Luo SD, Chen WC, Wu CN, Yang YH, Li SH, Fang FM, Huang TL, Wang YM, **Chiu TJ**, Wu SC. Low-Dose Aspirin Use Significantly Improves the Survival of Late-stage NPC: A Propensity Score-Matched Cohort Study in Taiwan. *Cancers (Basel)*. 2020 Jun 12;12(6):E1551. doi: 10.3390/cancers12061551.
28. **Chiu TJ**, Hsieh MJ, Lin YC, Weng CC, Weng YT, Hsiao CC, Cheng KH. Inactivation of APC Induces CD34 Upregulation to Promote Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits in Pancreatic Cancer. *Int J Mol Sci*. 2020 Jun 23;21(12):E4473. doi: 10.3390/ijms21124473.
29. Tsai MH, Chuang HC, Lin YT, Lu H, Fang FM, Huang TL, **Chiu TJ**, Li SH, Chien CY. Predictors of hospital expenses and hospital stay among patients undergoing total laryngectomy: Cost effectiveness analysis. *PLoS One*. 2020 Jul 16;15(7):e0236122. doi:10.1371/journal.pone.0236122. eCollection 2020.

Curriculum Vitae

Name : 吳佳哲 Wu Chia-Che

E-Mail : wu.chiache@msa.hinet.net

Address:

No. 123, Ta-Pei Road, Niasung District, Kaohsiung city, Taiwan 833 Office

TEL: 886-7-7317123 ext 8303

Education :

1994~1997 : Kaohsiung Municipal Kaohsiung Senior High School 1998~2006 :
Chinese Medical University, Taichung, Taiwan, M.D.

Employment Record :

2004~2005 : Internship, Chinese Medical University Hospital, Taichung, Taiwan

2005~2006 : Chinese Medicine Internship, Kaohsiung Municipal Chinese
Medical

Hospital, Kaohsiung, Taiwan

2007~2010 : Internal medicine residency, Department of Internal Medicine,
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

2010~2012 : Research Fellow, Department of Internal Medicine, Division of
Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan

2012~Now : Visiting Attending, Department of Internal Medicine, Division of
Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan

Poster:

1. **C.-C. Wu**, K.-M. Rau, M.-C. Hsieh, Y.-L. Su. Comparison of cisplatin versus carboplatin chemotherapy for metastatic urothelial carcinoma in patients with stage III chronic kidney disease. ESMO Asia 2018 Congress Abstract 369

Publication:

1. Chang-Ting Lin, Po-Jung Su, Shih-Yu Huang, **Chia-Che Wu**, Hung-Jen Wang, Yuan-Tso Cheng, Hao-Lun Luo, Chien-Hsu Chen, Ting-Ting Liu, Chun-Chieh Huang, Yu-Li Su. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. J Immunother . 2022 Sep 20.
2. Yu-Li Su, Kai-Lung Tsai, Tai-Jan Chiu, Yueh-Ming Lin, Ko-Chao Lee, Chien- Chang Lu, Hong-Hwa Chen, **Chia-Che Wu**, Hung-Chih Hsu. Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment. Cancers (Basel) . 2021 Oct 11;13(20):5080
3. Huang SY, **Wu CC**, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su HY. Comparative Study of the Safety and Efficacy of

First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma. *Oncology*. 2020;98(3):146-153. doi: 10.1159/000504393. Epub 2019 Dec 3.

4. Ming-Chun Kuo, Po-Jung Su, Chun-Chieh Huang, Hao-Lun Luo, Tai-Jan Chiu , Shau-Hsuan Li, **Chia-Che Wu**, Ting-Ting Liu, Yuan-Tso Cheng, Chih-Hsiung Kang, Yu-Li Su Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice. *Front Oncol* . 2020 Nov 27;10:584834. doi: 10.3389/ fonc.2020.584834. eCollection 2020
5. **Chia-Che Wu**, Kun-Ming Rau, Wei-Chieh Lee, Meng-Che Hsieh, Jia-Sin Liu, Yen-Yang Chen, and Harvey Yu-Li Su. Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. *J Clin Med*. 2019 Jul 12;8(7). pii: E1024. doi: 10.3390/jcm8071024.
6. **Wu CC**, Li SH, Lu HI, Lo CM, Wang YM, Chou SY, Chen YH. Inflammation- based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis. *PeerJ*. 2018 Sep 19;6:e5655. doi: 10.7717/peerj.5655. eCollection 2018.
7. Chien TL, Rau KM, Chung WJ, Tai WC, Wang SH, Chiu YC, Wu KL, Chou YP, **Wu CC**, Chen YH, Chuah SK; Gastric Cancer Team. Trousseau's syndrome in a patient with advanced stage gastric cancer. *World J Gastroenterol*. 2015 Sep 14;21(34):10049-53. doi: 10.3748/wjg.v21.i34.10049.
8. **Chia-Che Wu**, Meng-Chih Lin, Jui-Long Wang, Kun-Ming Rau, Yen-Yang Chen, Cheng-Hua Huang. Pemetrexed as Third-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer (NSCLC): A Retrospective Analysis. *台灣癌症醫學雜誌*；27 卷 4 期 (2011 / 08 / 01) , P157 - 164